Previous studies have shown that low expression of LCN2, ATM, and ATP1 increases the sensitivity of tumor cells to cisplatin (Matassa et al., 2016; Zhang et al., 2017; Huang et al., 2019). The gene discussed is LCN2; the disease is neoplasm.